ConductScience.org, home

Trial · NCT02612480

Registered outcomes22

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
Primaryconcentration plasma TNFalpha (pg/ml)measured after challenge with endotoxin at day 7 of medicationmeasured with Luminex assay
Secondaryconcentration plasma IL-6 (pg/ml)measured after challenge with endotoxin at day 7 of medicationmeasured with Luminex assay
Secondaryconcentration plasma IL-8 (pg/ml)measured after challenge with endotoxin at day 7 of medicationmeasured with Luminex assay
Secondaryconcentration plasma IL-10 (pg/ml)measured after challenge with endotoxin at day 7 of medicationmeasured with Luminex assay
Secondaryconcentration plasma IL-1RA (pg/ml)measured after challenge with endotoxin at day 7 of medicationmeasured with Luminex assay
Secondaryconcentration plasma IL-1beta (pg/ml)measured after challenge with endotoxin at day 7 of medicationmeasured with Luminex assay
Secondaryconcentration plasma MCP-1(pg/ml)measured after challenge with endotoxin at day 7 of medicationmeasured with Luminex assay
Secondaryconcentration plasma MIP-1a(pg/ml)measured after challenge with endotoxin at day 7 of medicationmeasured with Luminex assay
Secondaryconcentration plasma MIP-1b(pg/ml)measured after challenge with endotoxin at day 7 of medication
Secondaryconcentration plasma IFNgamma(pg/ml)measured after challenge with endotoxin at day 7 of medicationmeasured with Luminex assay
Secondaryplasma adenosinemeasured after challenge with endotoxin at day 7 of medication
Secondaryplatelet monocyte complexesmeasured after challenge with endotoxin at day 7 of medicationflowcytometric determination of monocytic load with platelets
Secondaryplatelet neutrophil complexesmeasured after challenge with endotoxin at day 7 of medicationflowcytometric determination of neutrophil load with platelets
Secondaryplatelet reactivitymeasured after challenge with endotoxin at day 7 of medicationex vivo stimulation of platelets with ADP and collagen, response measured as P-selectin and fibrinogen)
Secondarymonocytic tissue factor expressionmeasured after challenge with endotoxin at day 7 of medicationtissue factor expression on monocytes as measured by flow cytometry
Secondarymonocytic HLA-DR expressionmeasured after challenge with endotoxin at day 7 of medicationas measured by flow cytometry
SecondaryCD14/16 ratiomeasured after challenge with endotoxin at day 7 of medicationmeasured with flow cytometry
Secondaryplatelet von Willebrandfactor expressionmeasured after challenge with endotoxin at day 7 of medicationmeasured with flow cytometry
SecondaryVASP-Pdifference between measurement prior to start of study drug after challenge with endotoxin at day 7 of medicationELISA
Secondarysymptoms during endotoxin daymeasured after challenge with endotoxin at day 7 of medication6 point likert scale

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02612480/registered